AOC Highlights Pharma Patent Evergreening with Humira and AstraZeneca Inhaler Examples
Embed this grade
Unlock the full scoreboard
Letter grade, factuality, lean, and rationales — free with registration. No card required.
See grades free How grading works
Already have an account? Sign in. The full report below is free to read.
Disagree with this grade or political lean?
Flagging is open to every reader with a free account. Sign in or create one to dispute this report.
Topics in this report
Summary
The Forbes Breaking News segment aired Rep. Alexandria Ocasio-Cortez's questioning of Dr. Hwang (likely Dr. Thomas Hwang) during a July 2026 House Energy & Commerce Health Subcommittee hearing on the U.S. pharmaceutical patent system. AOC contrasted genuine innovation with alleged abuses, focusing on how companies file secondary patents on minor reformulations to extend market exclusivity beyond the standard 20 years from filing. She presented physical examples of Humira syringes and an AstraZeneca asthma inhaler, arguing these tactics keep prices high for patients.
The witness confirmed the basic mechanics of patent review and exclusivity, agreed that most reformulations serve to extend life cycles rather than advance care, and stated such strategies reward legal maneuvers over basic science. No additional witnesses or opposing views were shown in the clip; the segment relied on AOC's prepared examples and the doctor's affirmations.
Editorial Assessment
The broadcast accurately captures widespread concerns about patent evergreening documented in studies from I-MAK, UC Law SF's Robin Feldman, and others, where secondary patents on minor changes (formulations, devices) frequently delay generic entry and sustain high prices. Humira's patent thicket of 130-250 filings and price escalations to ~$3,000 per syringe (~$77,000-$80,000 yearly) are corroborated by congressional records, NYT reporting, and AbbVie critiques. The inhaler cap example reflects real FTC and public criticism of device patents on asthma inhalers. Viewers miss context that effective market exclusivity often averages 11-14 years due to development timelines, not the full 20; some reformulations improve adherence or reduce side effects; and patents must still meet novelty/non-obviousness standards (though critics argue USPTO grants many weak ones). The framing leans heavily toward portraying industry practices as exploitative without balancing R&D incentives or noting post-2023 Humira biosimilar entry lowered prices significantly in some markets.
Key Moments
Pharma patent system grants 20 years exclusivity from filing for new drugs to recoup investment.
Confirmed by USPTO and FDA rules; actual effective exclusivity is typically shorter (~11-14 years average per studies).
AbbVie obtained over 130 patents on Humira via minor changes, driving price from $500 to $3,000 per syringe (~$80k/year).
Supported by I-MAK (247 patents cited), NYT (price hikes ~30 times, $114B revenue post-2016), congressional testimony.
AstraZeneca patented a minor plastic piece on an asthma inhaler (to keep cap attached) with no change to medication, extending exclusivity.
Widely reported in AOC's own release, social media, and academic papers on device evergreening; aligns with FTC involvement in inhaler patent disputes.
In vast majority of cases, these reformulations are life-cycle extending rather than patient-beneficial.
Studies (Feldman, Gupta) show secondary patents extend monopoly ~3 years on average and raise costs, but some changes improve usability; USPTO 2024 study found more patents do not always equal longer exclusivity.
These strategies reward aggressive legal maneuvers instead of risky basic science.
Witness opinion in hearing; critics agree but industry argues follow-on patents incentivize incremental improvements that enhance safety/efficacy.
Notable Concerns
- One-sided presentation without pharma perspective or data on average effective exclusivity periods
- Vague on "vast majority" of reformulations being unnecessary, as literature notes some deliver clinical value
- Physical prop demonstration risks oversimplifying complex patent law and FDA Orange Book listings
Sources Consulted
- How a Drug Company Made $114 Billion by Gaming the U.S. Patent System
- Ocasio-Cortez Slams Big Pharma for Gaming U.S. Patent System
- Drug Patent and Exclusivity Study
- The Evergreening Playbook: How Pharma Extends Drug Exclusivity
- How Drugmakers Use the Patent Process to Keep Prices High
- May Your Drug Price Be Evergreen
- AbbVie Repeatedly Hiked Humira Prices and Abused U.S. Patent System
- Fact Check: Debunking the Patent 'Evergreening' Myth